LOS ANGELES, March 7, 2016 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today
announced that Andrew Gengos, Chief
Executive Officer of ImmunoCellular, will present a corporate
overview and business update at the 28th Annual ROTH
Conference on Wednesday, March 16,
2016 at 8:30 am PT, at the
Ritz-Carlton Hotel, Laguna Niguel,
CA.
To access the live audio webcast of the ROTH presentation,
please log on through a link located in the Investors section of
ImmunoCellular's website at www.imuc.com, under the Events &
Presentations tab. A replay of the webcast will be available one
hour after the conclusion of the live event.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that
is developing immune-based therapies for the treatment of brain and
other cancers. The phase 3 registrational trial of lead product
candidate, ICT-107, a dendritic cell-based immunotherapy targeting
multiple tumor-associated antigens on glioblastoma stem cells, is
open for patient screening. ImmunoCellular's pipeline also
includes: ICT-121, a dendritic cell immunotherapy targeting the
CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a
dendritic cell immunotherapy targeting antigens on ovarian cancer
stem cells; and the Stem-to-T-cell research program which engineers
the patient's hematopoietic stem cells to generate antigen-specific
cancer-killing T cells. To learn more about ImmunoCellular, please
visit www.imuc.com.
Contact:
For ImmunoCellular Therapeutics, Ltd.
Jane Green.
Investor Relations
415.348.0010
jane@jmgcomm.com
Logo -
http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-to-present-at-roth-conference-on-march-16-2016-300231165.html
SOURCE ImmunoCellular Therapeutics, Ltd.